You are currently browsing the tag archive for the ‘Challenges of Open Source Drug Initiatives’ tag.

This post is provided by Suela Simoni, Student Assistant at Innsbruck University

While the concept of “open source” emerged as a radically open and transparent way of developing software, it is increasingly applied in other contexts as well. In pharmaceutical open source projects, for example, anyone can contribute at any time to the project, methods and data are in the public domain, and data is released as soon as it is acquired. However, compared to the software industry, open source approaches struggle to take ground in the pharma industry. As of December 2021 there has not been a single molecule worldwide, which has been discovered, developed, and brought to market completely open source. There are a few examples of patent-free molecules that have been going through clinical trials: one is the Praziquantel and the second one is the Fexinidazole. Since only a part of the process has been done openly in these cases, they cannot be considered to be completely ‘open source’. Using the example of the initiative “Open Source Malaria” and outlining the challenges they face, I will discuss why developing drugs and vaccines based on open source principles represents a difficult endeavor.

Read the rest of this entry »

The Book

Governance across borders: transnational fields and transversal themes. Leonhard Dobusch, Philip Mader and Sigrid Quack (eds.), 2013, epubli publishers.
January 2022
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  

Twitter Updates

Copyright Information

Creative Commons License
All texts on governance across borders are licensed under a Creative Commons Attribution-Share Alike 3.0 Germany License.